Storia in 1 fonti

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.

Raccontata da

cnbc.com

Timeline cronologica

mercoledì 29 luglio 2026·cnbc.com
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.